Terminated at 14 patients: the feasibility study the organoid field needed

What the work claims

This is a terminated clinical study record, not a paper, so the claim is in the design rather than any result. The study proposed to test whether a bundle of personalized assays, patient-derived organoid culture with drug screening, circulating tumor DNA (ctDNA) quantification across time points, plus structured surveys of whether oncologists found the outputs useful, could be delivered reliably to patients with resectable biliary tract cancer without changing their standard treatment.¹

Two design choices deserve credit. First, the primary endpoints were operational: the success rate of organoid culture and drug screen within 12 weeks after surgery, and the success rate of obtaining ctDNA quantification with measurable change across time points. Second, it was explicitly observational, promising no change to standard care. This is the correct order of operations for organoid medicine: prove the platform delivers before claiming it predicts.

How it works

Biliary tract cancers are rare and genomically heterogeneous, which makes them a reasonable stress test for a profiling platform: if the workflow can deliver organoid cultures and drug screens from small resected specimens on a clinical clock, it can probably do so elsewhere. The study paired two complementary readouts. Organoid drug screening is a functional measurement: it asks, directly, what the living tumor cells respond to. ctDNA is a molecular tracking measurement: it asks whether tumor burden, as read from blood, falls or rises across treatment. The registry record also registers physician-facing outcome surveys, an underused instrument: a test that cannot change a decision is inert no matter how accurate it is.¹

Where a skeptic should push

The load-bearing assumption in any feasibility study is that feasibility is worth measuring on its own terms, and here the record itself undercuts the attempt. Actual enrollment was 14 patients across more than four years at two academic centers (University of Washington, Seattle and University of Illinois at Chicago). The record gives the reason for termination in five words: "study terminated due to end of funding." Primary completion is listed as December 2024, with the study formally completed in April 2025 and last updated that July. No results module exists, so the fourteen patients' data, including the single number the field most needs, the twelve-week organoid establishment rate, are not retrievable from the public record.¹

Separate demonstrated from asserted: nothing in the record demonstrates anything about organoid performance in biliary cancer. What it demonstrates is something about the economics: a per-patient workflow combining organoid culture, drug screening, serial ctDNA, and survey instruments is expensive to run in a rare cancer where accrual is slow, and the funding model (the record implies a grant cycle) did not span the time the science needed. The generalization gap a peer reviewer would flag is also the obvious one: even if the fourteen-patient run had succeeded, a two-center, case-only feasibility cohort could not establish that the platform generalizes beyond expert hands.

The missing base rates of organoid platforms

For organoid models of human organs and the drug discovery work built on them, the uncomfortable implication is that the field's foundational denominator is measured almost nowhere. Every organoid-guided trial implicitly assumes a establishment rate, a turnaround time, and a per-patient cost, yet these numbers are published selectively, by successful labs, in successful papers. A terminated feasibility study with no results module is precisely where those base rates go to die: the fourteen patients almost certainly generated exactly the data (how often did culture succeed within twelve weeks? how often did the drug screen return before the treatment decision was moot?) that vendors and trialists cite from happier cohorts.

The opportunity is concrete: feasibility endpoints like this trial's, success rate within a clinical window, time-to-result, proportion of screens that inform a decision, are cheap, registerable, and genuinely predictive of whether downstream efficacy trials can even run. A funder or regulator that mandated a feasibility primary endpoint for every interventional organoid trial, and required results posting even on termination, would do more for the credibility of organoid drug discovery than another decade of concordance studies. The threat is the mirror image: if feasibility keeps failing quietly, the efficacy literature built on top of it inherits a hidden survival bias, and the field's quoted success rates stay calibrated to the laboratories that never needed the feasibility study in the first place.

The bottom line

Established fact, from the registry: a well-designed feasibility study of organoid and ctDNA profiling in resected biliary tract cancer ran from July 2020, enrolled 14 patients, stopped for lack of funding, and posted no results. Hypothesis: its unpublished dataset holds the base rates the organoid field needs. What would confirm or refute that is not another award but a requirement, from funders, journals, or the registry itself, that terminated feasibility studies post their operational outcomes. Until then, treat every quoted organoid establishment rate as a survivor's statistic, and treat this record as the visible tip of a mostly invisible attrition problem.